ArticleBMC microbiology2025
Molecular epidemiology, antimicrobial resistance, and virulence determinants of Enterococcus faecium bloodstream isolates: a 7-year study in Shandong, China.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comparative genomic characterization and antimicrobial resistance of bacteremia-causingMicrobiology spectrum · 2026Article
- Impact of Vancomycin Resistance on 30-Day Mortality in Solid Organ Transplant Recipients withAntibiotics (Basel, Switzerland) · 2026Article
- Clinical characteristics, predisposing factors and outcomes ofFrontiers in cellular and infection microbiology · 2026Article
- Distribution and Antimicrobial Resistance Trends of Bloodstream Bacterial Isolates: A 10-year Single-Center Study in China.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEnterococcus faecium is a major cause of hospital-acquired infections, particularly bloodstream infections, which are associated with high mortality rates. This study aimed to characterize the molecular epidemiology, antimicrobial resistance profiles, and virulence determinants of E. faecium isolates from bloodstream infections in a tertiary hospital in Shandong, China, over a seven-year period (2017-2023).
resultsAmong 91 E. faecium isolates, 4 were vancomycin-resistant (VREfm), and 87 were vancomycin-susceptible (VSEfm). High resistance rates (> 87.9%) were observed for ciprofloxacin, levofloxacin, penicillin, ampicillin, and erythromycin. Multilocus sequence typing (MLST) identified 16 sequence types (STs), dominated by ST78 (41.8%) and ST555 (22.0%), with a novel ST designated ST2760. Notably, the prevalence of ST555 increased significantly from 18.2% in 2021 to 43.8% in 2023. Thirteen of the 16 STs (95.6% of isolates) were assigned to Clonal Complex 17 (CC17), while ST775, ST922, and the novel ST2760 were phylogenetically distinct from this predominant lineage. Virulence gene analysis revealed high detection rates (> 73%) of adhesion-associated genes (pilA, pilB, acm, sgrA, scm, esp, and ecbA). The pilA gene was significantly more prevalent in ST78 (92.1%) than in ST555 (40.0%), conferring higher biofilm-forming capacity. The absence of pilA in ST555 strains prior to 2021 correlated with lower detection rates, while its emergence post-2021 coincided with enhanced environmental fitness and increased clinical prevalence.
conclusionThis study highlights the predominance of ST78 and ST555 in E. faecium bloodstream infections, with their increasing prevalence linked to acquisition of the pilA gene and enhanced environmental survival through biofilm formation. The identification of a novel ST2760 underscores the ongoing genetic diversity of E. faecium. These findings provide critical insights for optimizing infection control strategies and guiding empirical therapy for E. faecium bloodstream infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.